From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. Dermatology>
  4. Summary and Comment

Is PLC a Clonal T-Cell Lymphoproliferative Disorder?

The nature of pityriasis lichenoides chronica (PLC) and its relationship to pityriasis lichenoides et varioliformis acuta (PLEVA) and mycosis fungoides (MF) remain enigmatic. Recently, evidence of clonal proliferation has been reported in cases of PLEVA, strengthening the evidence that these entities may be part of a spectrum of lymphoproliferative disorders. The present study evaluated biopsies from 6 patients with PLC for the presence of clonal T-cell gene rearrangements. In addition, the researchers performed immunophenotyping of the infiltrating lymphocytes.

All patients demonstrated a classic combination of clinical and histologic features of the disease. A clonal rearrangement was detected in 3 of the 6 cases. All cases demonstrated a predominance of CD4+ infiltrates. The authors suggest that these findings provide additional evidence that PLC, PLEVA, and MF are related.

Comment: The data are very convincing, but caution is nonetheless essential in interpreting the findings. While clonality has been associated with lymphomas and may portend an aggressive clinical course, evidence is mounting that not all clonal processes result in adverse outcomes. The/significance of clonality within cutaneous T-cell infiltrates remains to be seen. Long-term follow-up studieswith large numbers of patients will be necessary before anydefinitive statements can be made.

— BR Smoller

Published in Journal Watch Dermatology May 3, 2001

Citation(s):

Shieh S et al. Differentiation and clonality of lesional lymphocytes in pityriasis lichenoides chronica. Arch Dermatol 2001 Mar 137 305-308.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2001. Massachusetts Medical Society. All rights reserved.